DEXERYL Emollient Cream

Statistically significant effectiveness proven in clinical studies on over 1000 patients. These studies were conducted against a placebo or comparator, providing the highest level of scientific evidence

Discover the Emollient Cream


Significant reduction in the severity of radiotherapy-related erythema

Regular application of Dexeryl Emollient Cream three times a day for 42 days significantly reduced the severity of radiotherapy-related erythema compared to a leading product¹

md_dexeryl_website-radiotherapy-erythema-results-graph 577x440  Graphique représentant l’intensité de l’érythème, à 42 jours, selon le produit utilisé. 1- Erythème mineur. 2- Erythème modéré. 3- Erythème sévère. Graphique créé par Pierre Fabre.



To compare the activity and tolerability of DEXERYL versus Trolamine in the management of post-radiotherapy erythema.  


Phase III, single-centre, randomised (contralateral), double-blind study of Dexeryl cream versus Trolamine 0.67% (reference product).


80 randomised adult patients: 70 with breast cancer/10 with ENT cancer.


3 applications daily.


Duration of 12 weeks: 3 applications per day during the first 6 weeks of radiotherapy and then 6 weeks after it has finished.

Primary evaluation criteria

Trophic aspect of treated skin surfaces at D42 (end of radiotherapy) assessed by clinical signs (pain, erythema, exulceration, exudation) using a semi-quantitative scale with 4 scores (0=absent, 1=slight, 2=moderate, 3=severe) and a visual analogue scale assessing the overall trophic aspect of the skin (0: skin lesion - 100: no skin lesion)

Secondary evaluation criteria

  • Clinical presentation of treated skin surfaces at D7, D14, D21, D28, D35 and D84 (same parameters as at D42)
  • Average time to first skin lesions
  • Treatment efficacy assessed by the patient using a visual analogue scale
  • Average time of disappearance of skin lesions between D42 and D84
  • Acceptability and ease of use of the two treatments evaluated on D7, D42 and D84 according to 3 criteria: ease of application, quality of penetration and sensation after application
  • Final evaluation of treatments on D84 according to 5 criteria: treatment efficacy, treatment tolerance, treatment failure in terms of non-compliance, inefficacy and adverse events, preference for one of the treatments and residual hyperpigmentation.


Tolerance is satisfactory for both products.

How do you take care of your skin when you have cancer?

How do you take care of your skin when you have cancer?

Cancer treatments can cause changes to the skin and nails.

How can you take care of your skin to minimise their occurrence?

Understanding skin and cancer


1- Monnier A. Study of the activity and tolerance of DEXERYL cream versus Trolamine in the treatment of erythema resulting from radiotherapy. Clinical study report DC569 B98 CR301. 

Back to top